iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea · Delayed Price · Currency is KRW 4,060.00
-20.00 (-0.49%)
Apr 1, 2026, 3:30 PM KST
iNtRON Biotechnology Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,740 | 6,418 | 9,585 | 14,007 | 29,308 |
Other Revenue | - | - | -0 | -0 | - |
| 5,740 | 6,418 | 9,585 | 14,007 | 29,308 | |
Revenue Growth (YoY) | -10.56% | -33.05% | -31.57% | -52.21% | -35.49% |
Cost of Revenue | 2,695 | 2,738 | 3,802 | 4,412 | 7,614 |
Gross Profit | 3,045 | 3,679 | 5,783 | 9,595 | 21,694 |
Selling, General & Admin | 5,094 | 4,562 | 6,041 | 5,763 | 6,521 |
Research & Development | 4,655 | 3,478 | 3,174 | 3,312 | 3,553 |
Amortization of Goodwill & Intangibles | 242.37 | 252.12 | 237.95 | 214.92 | 199.43 |
Other Operating Expenses | 227.52 | 199.93 | 212.56 | 270.75 | 317.09 |
Operating Expenses | 10,949 | 8,917 | 9,068 | 11,075 | 11,617 |
Operating Income | -7,904 | -5,238 | -3,285 | -1,479 | 10,077 |
Interest Expense | -89.93 | -23.41 | -2,919 | -3,506 | -1,636 |
Interest & Investment Income | 1,124 | 1,575 | 2,874 | 1,714 | 507.13 |
Earnings From Equity Investments | -863.5 | -186.27 | 228.32 | 172.72 | - |
Currency Exchange Gain (Loss) | -106.79 | 252.37 | 328.59 | 1,259 | 1,268 |
Other Non Operating Income (Expenses) | 48.82 | 77.51 | -328.16 | 11,371 | -39.13 |
EBT Excluding Unusual Items | -7,792 | -3,543 | -3,101 | 9,531 | 10,178 |
Gain (Loss) on Sale of Investments | -1,085 | -96.64 | -1,986 | -1,142 | 443.93 |
Gain (Loss) on Sale of Assets | -157.39 | 633.68 | 6.08 | -70.58 | -46.75 |
Other Unusual Items | - | - | -5,756 | - | - |
Pretax Income | -9,033 | -3,006 | -10,837 | 8,319 | 10,575 |
Income Tax Expense | -74.99 | -414.72 | -1,141 | 2,607 | 846.81 |
Earnings From Continuing Operations | -8,958 | -2,591 | -9,695 | 5,712 | 9,728 |
Net Income | -8,958 | -2,591 | -9,695 | 5,712 | 9,728 |
Net Income to Common | -8,958 | -2,591 | -9,695 | 5,712 | 9,728 |
Net Income Growth | - | - | - | -41.28% | -34.92% |
Shares Outstanding (Basic) | 32 | 33 | 33 | 34 | 34 |
Shares Outstanding (Diluted) | 32 | 33 | 33 | 34 | 34 |
Shares Change (YoY) | -3.49% | -1.18% | -2.16% | 0.58% | -4.41% |
EPS (Basic) | -283.00 | -79.00 | -292.11 | 168.38 | 288.42 |
EPS (Diluted) | -283.00 | -79.00 | -292.11 | -0.34 | 288.00 |
EPS Growth | - | - | - | - | -25.98% |
Free Cash Flow | -7,679 | -1,260 | -4,673 | 3,748 | 13,427 |
Free Cash Flow Per Share | -242.57 | -38.43 | -140.80 | 110.49 | 398.07 |
Gross Margin | 53.05% | 57.33% | 60.33% | 68.51% | 74.02% |
Operating Margin | -137.69% | -81.61% | -34.27% | -10.56% | 34.38% |
Profit Margin | -156.06% | -40.37% | -101.15% | 40.78% | 33.19% |
Free Cash Flow Margin | -133.77% | -19.64% | -48.75% | 26.76% | 45.81% |
EBITDA | -5,958 | -3,212 | -1,373 | 87.7 | 11,614 |
EBITDA Margin | -103.79% | -50.05% | -14.33% | 0.63% | 39.63% |
D&A For EBITDA | 1,946 | 2,026 | 1,912 | 1,567 | 1,536 |
EBIT | -7,904 | -5,238 | -3,285 | -1,479 | 10,077 |
EBIT Margin | -137.69% | -81.61% | -34.27% | -10.56% | 34.38% |
Effective Tax Rate | - | - | - | 31.34% | 8.01% |
Advertising Expenses | 73.4 | 41.67 | 70.63 | 29.69 | 34.6 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.